Press Releases

Press Releases

DateTitle 
May 10, 2022
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs – mupadolimab (anti-CD73), ciforadenant (adenosine 2A receptor antagonist) and CPI-818 (ITK inhibitor)
May 05, 2022
Corvus to Host R & D Symposium on May 10 BURLINGAME, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the quarter ended March
Apr 26, 2022
Company to host a webcast at 9:00am ET / 6:00am PT BURLINGAME, Calif. , April 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will host an R&D Symposium to provide an update on the
Mar 10, 2022
Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported
Mar 03, 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , March 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March
Jan 13, 2022
BURLINGAME, Calif. , Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China , Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase